The GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] Access Program Advisory Board has recommended, and Axios Healthcare Development (AHD) has subsequently approved, applications from 23 organizations and institutions in 20 lowest-income countries.
More than one million doses of GARDASIL, enough to vaccinate more than 349,000 eligible girls, have been approved by AHD for donation to this current group of 23 program participants.
More than 665,600 doses of GARDASIL have shipped to 15 participants, in support of their proposed HPV-vaccination projects in 14 countries: Bhutan, Bolivia, Cambodia, Cameroon, Georgia, Ghana, Haiti, Kiribati, Lesotho, Moldova, Nepal, Tanzania, Uganda and Uzbekistan.
These 15 participants have completed seven HPV vaccination projects in six countries: Bhutan, Bolivia, Cambodia, Haiti, Lesotho and Nepal.
There are ten ongoing HPV-vaccination projects in nine countries: Bolivia, Cambodia, Cameroon, Georgia, Lesotho, Moldova, Uganda, Uzbekistan and Tanzania.
Axios Healthcare Development routinely interviews all GARDASIL Access Program participants and analyzes their formal progress reports to synthesize lessons learned from the program. AHD also publishes semiannual program newsletters highlighting the experiences of participants.
